Delaware
|
001-34079
|
11-3516358
|
(State or other jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
15245 Shady Grove Road, Suite 455
Rockville, MD
|
20850
|
(Address of principal executive offices)
|
(Zip Code)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.0001 par value
|
RNN
|
NYSE American
|
Emerging growth company ☐
|
Director
|
For
|
Withhold
|
Broker Non-Votes
|
|||
Charles Beever
|
446,331
|
86,786
|
2,365,809
|
|||
Peter Brandt
|
445,231
|
87,886
|
2,365,809
|
|||
Kwang Soo Cheong
|
445,954
|
87,163
|
2,365,809
|
|||
Ben Gil Price
|
447,705
|
85,412
|
2,365,809
|
|||
Richard J. Rodgers
|
448,150
|
84,967
|
2,365,809
|
|||
Lara Sullivan
|
449,060
|
84,057
|
2,365,809
|
|||
Douglas J. Swirsky
|
447,193
|
85,924
|
2,365,809
|
For
|
Against
|
Abstain
|
||
2,727,259
|
126,138
|
45,529
|
REXAHN PHARMACEUTICALS, INC.
|
|
Date: June 7, 2019
|
/s/ Douglas J. Swirsky
|
Douglas J. Swirsky
|
|
President and Chief Executive Officer
|